Navigation Links
Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting

GERMANTOWN, Md., April 10, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that AVN944 will be the subject of three poster presentations at the American Association for Cancer Research 2007 Annual Meeting to be held on April 14-18, 2007 in Los Angeles, Calif.

The first poster presented by Avalon, will review the data derived from the Avalon ongoing Phase I clinical trial of AVN944 for the treatment of hematological cancers. The poster is titled, "The Modulation of Gene Expression and Guanosine Pools by Inhibition of Inosine Monophosphate Dehydrogenase (IMPDH); correlating In Vitro Cell Resistance with Biomarker Response in Patient Samples from the Phase I Trial." This poster will provide data from clinical samples that correlate IMPDH inhibition, GTP pool suppression, and associated changes in tumor cell gene expression. The presentation will be Monday, April 16, 2007 from 8 a.m. until noon Pacific Time.

The second Avalon poster presentation is titled, "Antiangiogenic Properties of AVN944, A Potent Inhibitor of IMPDH." The poster will describe in vitro and in vivo experiments that reveal the effects of AVN944 on blood vessel formation. The presentation will be on Tuesday, April 17, 2007 from 8 a.m. until noon Pacific Time.

Another poster that will discuss AVN944 will be presented by the lab of Dr. Beverly Mitchell of Stanford University. The poster is titled, "GTP depletion induces translocation of TIF-IA and PAF53, inhibition of pre-rRNA synthesis and dislocation of nucleolar proteins." The presentation cites AVN944 as a compound that has effects on rRNA inhibition and nucleolar protein translocation. The poster presentation will be Tuesday, April 17, 2007 from 1 p.m. until 5 p.m. Pacific Time.

All three posters are in the Experimental and Molecular Therapeutics Poster Sessions.

AVN944 is an oral small molecule drug candidate that inhibits inosin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:
(Date:11/23/2009).../--HealthWarehouse.com,Inc.(OTCBulletinBoard:HEWA)...nancialresultsforthethirdquarterendedSeptember30,2...,drivenbyheavygrowthinprescriptionsalesandpharmacy...to34.6%andthenetlossforthequarterwas$619,114compar...ber30,2008. ,, "Wecontinuetoseeconsumerstransfe...
(Date:11/23/2009)...ll/--BostonScientificCorporation(NYSE: BSX )issche...rence,December1-2. ,, RayElliott,PresidentandCh...ntandChiefFinancialOfficer,willparticipateina30-mi...,beginningatapproximately9:00a.m.E.T. ,, Alivew...edpartiesatBostonScientific,swebsiteat www.bostons...
(Date:11/23/2009)...FirstCall/--BeckmanCoulter,Inc.(NYSE: BEC ),aleadi...simplify,automate,andinnovatecomplexbiomedicaltest...vicepresidentofstrategy,willpresentatthePiperJaffr...12:00p.m.(ET). ,, (Logo: http://www.newscom.com...astofBeckmanCoulter,spresentationcanbeaccessedbyvi...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 1Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 2Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 1Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 2Study shows how to boost value of Alzheimers fighting compounds 54660 1Study shows how to boost value of Alzheimers fighting compounds 54660 2
...hown to Be Safe and Effective for Menopausal ..., Fla., Oct. 3 A study presented today,at the 200...ociety (NAMS),revealed that Divigel(R) (estradiol ...severity of moderate to severe hot flashes associa...he meeting found that Divigel(R),is a safe and wel...
...Systems Incorporated,(Nasdaq: IMCL ) and Bristol-...,that the U.S. Food and Drug Administration (FDA) ...b) product labeling to include overall survival,da...hibitor,(EGFR)-expressing metastatic colorectal ca...can- and oxaliplatin-based regimens. The approval...
Other Medicine Technology:New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
(Date:11/24/2009)... But the herbal supplement may help ward off peri... , TUESDAY, Nov. 24 (HealthDay News) -- Among peo...o biloba does not prevent heart attacks, stroke or...ence that the popular herbal remedy might help pre...al artery disease, however. , Ginkgo contains n...
(Date:11/24/2009)... , PHILADELPHIA Researchers have found that horm...at directly inhibits the growth of breast cancer. ...s a viable, well-tolerated agent for the treatment...dings published in Cancer Prevention Research , a...search. , "Hormones in pregnancy, such as estro...
(Date:11/24/2009)... ,, NEWYORK,Nov.24/PRNewswire-USNewswire/--T...lproblems.Itisharmreduction,offeringpragmaticandre...olproblemshavefailed.Spearheadingthismovementisagr...oderationSupport.HAMSisafree-of-charge,lay-ledsupp...,, TheNationalInstituteonAlcoholAbuseandAlcohol...
(Date:11/24/2009)... ,, BREWER,Maine,Nov.24/PRNewswire/--Thankst...nMaineHealthcareSystems(EMHS)andAnthemBlueCrossand...queIslecannow"visit"theirphysicianwithoutleavingho...endhealthrelatedmessagesandquestionsandcommunicate...nadditiontoschedulingappointments,checkingontestre...
(Date:11/24/2009)... , Reston, Va.SNM will hold its Conjoint Mid-Wint...e Convention Center in Albuquerque, N.M. This year...osium with the 2010 Annual Meeting and Educational...cine (ACNM), the Nanomedicine and Molecular Imagin... Workshop. The seven-day event offers participants...
Breaking Medicine News(10 mins):Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3Health News:Protein from pregnancy hormone may prevent breast cancer 2Health News:Harm Reduction for Alcohol: An Idea Whose Time Has Arrived 2Health News:The Doctor Will See You Now. . .Online 2Health News:SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location 2
...toona based bowling center offers chance to own a ... Special Olympics, ALTOONA, Pa., Nov. 12 "My eco...lect Barack Obama told fellow bowlers on a Saturda...bowlers in recent political history., On March 29...
...d net distribution helps prevent malaria, ALEPE, ...ethodist Church and their partners worldwide helpe...ainst Malaria launch an integrated health,campaign... of malaria., To view the Multimedia News Release...
...spitals that perform the heart procedure more ofte...v. 12 (HealthDay News) -- Heart attack patients wh...ity hospitals are more likely to survive if they,r...and used to inflate a tiny balloon that widens art...
...NTA MONICA, Calif., Nov. 12 Consumer,Watchdog cou...the mandatory,purchase of health insurance was pop...that voters overwhelmingly reject requiring proof ...lan and nearly,two-thirds (63%) were opposed when ...
...SHINGTON, Nov. 12 The Council for Quality,Respira...mmittee Chairman,Max Baucus (D-MT) for developing ... all Americans have access to high quality health ...o warned,that deep cuts in Medicare funding for ho...
...ST LANSING, Mich., Nov. 12 Lakshmi Kanta,Tummala ...Michigan State,Medical Society (MSMS) Alliance. Sh...ties of the 1,200-member organization that focuses...ouses founded in 1926, include educational program...
Other Medicine News:Health News:President Elect Barack Obama Bowling Lane Goes Up for Auction 2Health News:Photo: United Methodist Church, Partners Launch Life-Saving Campaign in Cote d'Ivoire 2Health News:With Angioplasty, More Is Better 2Health News:Home Oxygen Leaders Commend Sen. Baucus' Efforts to Expand Health Care Access, Warn That Deep Cuts in Oxygen Benefit May Undercut Access 2Health News:Lakshmi Kanta Tummala Serving as President of MSMS Alliance 2
High-sensitive CRP Control
MONO Mononucleosis Rapid Test Device
...Pipette Tracker pipette management software enable...lity assurance program. Use Pipette Tracker to cre...lly log data from PCS, set tolerances and immediat...ent and compliance reports. Pipette Tracker enable...
...Vance Male Sling System is an innovative, safe and...stress urinary incontinence in men following prost...t candidates for an artificial urinary sphincter d...acity or patient preference., ,InVance uses a ...
Medicine Products: